A bottom-up model from published epidemiology. Each patient group is sized separately - patients × annual price × share of patients treated at peak - across the major markets (US, Europe including the UK, Canada and Australia, plus Japan for Gorlin syndrome). Move the sliders to test the assumptions. These are estimates, not forecasts, and the rest of the world is excluded.
We focus on patients who keep developing new tumours. They are already under regular dermatology follow-up, carry the highest treatment burden and have the clearest case for a preventive medicine. The sliders start at our base case.
1. Gorlin syndrome and multiple basal cell carcinoma
Gorlin syndrome - our first indication. An inherited condition (PTCH1 mutation) affecting about 1 in 31,000 people - roughly 33,000 patients across the major markets. Patients develop basal cell carcinomas (BCCs) from early adulthood: a US registry reported a median of 8 new BCCs a year and over 200 in a lifetime, most treated surgically. Vismodegib is licensed only for advanced BCC, but NHS England funds it off-label for Gorlin syndrome; side effects mean treatment has to be intermittent. An orphan disease, with smaller trials and specialty pricing.
Multiple sporadic BCC. About 2 million people in the US and 180,000 in the UK develop a BCC each year. About 44% develop another within three years and around half within eight years. Target group: patients diagnosed with a BCC who have had at least one other in the previous five years - an estimated 1.0-1.5 million people a year.
Price - benchmarked on vismodegib. Our base case is £25,000 per patient per year. Since 2021 NHS England has routinely funded vismodegib, off-label, for adults with Gorlin syndrome and for adults with six or more BCCs, so payers already pay for drug treatment rather than repeated surgery in this group. Vismodegib's UK list price is £6,285 for 28 capsules - about £82,000 a year taken continuously, or roughly £54,000 a year on the intermittent schedule NHS England funds (about £75,000 for a 72-week course). It works - in Gorlin syndrome it cut new BCCs from 29 to 2 per patient per year - but muscle cramps, taste loss and hair loss force intermittent dosing and many patients stop. A well-tolerated preventive that can be used continuously could be priced well below vismodegib and still command £25,000 a year.
Gorlin syndrome
Estimate 30,000-35,000
Small, identified population under specialist care
Peak sales
How we estimate the patient numbers
Prevalence about 1 in 31,000, from a UK population study after improved case finding; the older, widely quoted estimate was 1 in 57,000.Evans DG et al. Am J Med Genet A 2010; Farndon PA et al. Lancet 1992; Lo Muzio L. Orphanet J Rare Dis 2008;3:32.
Applied to a major-market population of about 1.04 billion (US 335M, EU 450M, UK 68M, Japan 124M, Canada 40M, Australia 27M) this gives about 33,000 people.
Range 30,000-35,000. The true diagnosed number may be lower, as milder cases go unrecognised.
Burden: median 8 new BCCs a year and a mean of 312 in a lifetime in the US patient registry; before vismodegib, patients in the Gorlin trial extension had about 28 surgeries a year.US basal cell nevus syndrome patient registry, burden of illness report; Tang JY et al. 2016.
Current drug treatment: NHS England funds vismodegib off-label for Gorlin syndrome with six or more BCCs (at least three of 5mm or more), on an intermittent schedule. It expected about 22 Gorlin patients a year in England to be treated.NHS England Clinical Commissioning Policy 1905 (210504P), July 2021.
In development: patidegib, a topical hedgehog-inhibitor gel (Sol-Gel), has completed a phase 3 trial preventing new facial BCCs in Gorlin syndrome, with results expected in late November 2026.ClinicalTrials.gov NCT06050122.
Multiple sporadic BCC
Estimate 1.0-1.5 million
Typical specialty uptake 10-25%
Peak sales
How we estimate the patient numbers
People diagnosed with a BCC each year: US about 2.0 million, UK about 184,000, rest of Europe about 0.7 million (our estimate, at about 150 per 100,000), Australia about 0.3 million and Canada about 0.06 million - about 3.2 million in total.Asgari MM et al. JAMA Dermatol 2015; Kwiatkowska M et al. Skin Health Dis 2021.
Recurrence: 44% of BCC patients develop another BCC within three years, and 53% within a median of eight years.Marcil I, Stern RS. Arch Dermatol 2000;136:1524-30; Spanish BCC multiplicity cohort, Actas Dermosifiliogr 2025.
We take 30-45% of each year's BCC patients as having had another BCC in the previous five years, giving 1.0-1.5 million.
Japan is excluded because BCC is uncommon there.
Segment 1 peak sales
2. Multiple cutaneous squamous cell carcinoma
Transplant recipients. Organ transplant recipients have a 65-100x higher risk of cutaneous squamous cell carcinoma (cSCC), and their tumours are more aggressive. An estimated 0.8-1.0 million transplant recipients live in the major markets. Risk climbs steadily with time since transplant: in a UK cohort followed for a mean of ten years, 29% had developed skin cancer and two thirds of those had multiple tumours - about one in five of all recipients - and in Queensland 70% had skin cancer after 20 years. About three quarters of recipients who develop a first cSCC develop another within five years. The model starts from all living recipients; the share-treated slider covers both the fraction with recurrent cSCC (about one in five) and uptake among them.
Multiple sporadic cSCC. About 1.2-1.5 million people a year develop a cSCC across the major markets, and incidence is rising. In a nationwide Dutch study, 28% of patients developed a second cSCC within five years of their first, rising to 67% after a fifth. Target group: about 400,000-600,000 people with two or more cSCCs within five years.
Price - the same as BCC. We use the same £25,000 a year. cSCC is the more dangerous of the two cancers - it can spread and kill, particularly in transplant recipients - and the drugs used once it has spread, such as the immunotherapy cemiplimab, cost tens of thousands of pounds a year. Preventing it is worth at least as much as preventing BCC.
Transplant recipients
All living transplant recipients - estimate 0.8-1.0 million
About one in five have recurrent skin cancer; about half of them treated
Peak sales
How we estimate the patient numbers
Living organ transplant recipients: about 350,000 in the US in 2017 (220,000 kidney, 84,000 liver, 32,000 heart, 14,000 lung), now over 400,000. In Europe about 39% of the 1,074 people per million on kidney replacement therapy live with a functioning kidney transplant - about 220,000 people in the registry's 530 million population - with liver, heart and lung recipients in addition. With Canada and Australia this gives an estimated 0.8-1.0 million.OPTN/SRTR Annual Data Reports; ERA Registry Annual Report 2022.
Risk: cSCC is 65-100 times more common than in the general population, and the risk keeps rising with time since transplant - it roughly triples over 20 years.Mayo Clinic Proceedings, skin cancer in solid organ transplant recipients; Krynitz B et al. Int J Cancer 2013.
How many develop skin cancer: in a UK cohort of 931 recipients (mean 10.3 years since transplant), cumulative incidence was 11%, 25%, 54% and 74% at 5, 10, 20 and 30 years; 29% had already had skin cancer and 66% of them had multiple tumours. Twenty-year cSCC incidence is about 34% in the UK and 40% in the Netherlands. In Queensland, 45% of kidney recipients had skin cancer after 11 years and 70% after 20.Harwood CA et al. Am J Transplant 2013; Bouwes Bavinck JN et al. Transplantation 1996;61:715-21; review, Adv Clin Exp Med 2025.
Recurrence: after a first skin cancer, 59% of kidney recipients had another within three years and 72% within five. 74% of transplant recipients with a first cSCC develop another within five years, rising to 92% after several.Wisgerhof HC et al. Transplantation 2010; Eggermont C et al. J Am Acad Dermatol 2024.
Rates are lower in the US, where more recipients have darker skin: cSCC incidence of 812 per 100,000 person-years across 10,649 recipients, and 2% with multiple cSCC over a mean of seven years in a single-centre cohort of 3,652.Garrett GL et al. JAMA Dermatol 2017;153:296-303; Puza CJ et al. JAMA Dermatol 2018;154:727-8.
Our base case takes about one in five living recipients across the major markets as having recurrent skin cancer (the UK figure, with higher rates in Australia and lower in the US), with about half of them treated at peak - 10% of all recipients. Patients immunosuppressed for other reasons (for example chronic lymphocytic leukaemia) are not included.
Multiple sporadic cSCC
Estimate 400,000-600,000
Typical specialty uptake 10-25%
Peak sales
How we estimate the patient numbers
People diagnosed with a cSCC each year: US 0.7-1.0 million, UK about 51,000, rest of Europe about 0.18 million (our estimate, at about 40 per 100,000), Australia about 0.2 million and Canada about 0.03 million - 1.2-1.5 million in total.Karia PS et al. J Am Acad Dermatol 2013;68:957-66; Rogers HW et al. JAMA Dermatol 2015; Kwiatkowska M et al. Skin Health Dis 2021.
Recurrence: in a nationwide Dutch cohort of 12,345 patients, 28% developed a second cSCC within five years of their first, and the risk climbed with each further tumour, to 67% after a fifth.Eggermont C et al. J Am Acad Dermatol 2024.
We take 28-40% of each year's cSCC patients as having had another cSCC within five years, giving 400,000-600,000. Transplant recipients are counted separately.
Segment 2 peak sales
3. Combined opportunity
If a single drug could prevent both BCC and cSCC, it could serve both groups, starting with BCC and extending to cSCC. Many patients develop both tumour types, so the combined figure removes the overlap - an estimated quarter of the multiple sporadic cSCC group also falls in the multiple BCC group - rather than adding the two segments together.
Combined peak sales
Ceiling (everyone treated)
The base case gives combined peak sales of about £8.8bn a year (segment 1 about £5.1bn, segment 2 about £4.1bn), within a ceiling of about £46bn. The route is sequential: Gorlin syndrome first (orphan, small trials, clearest unmet need), then multiple BCC, then cSCC in transplant and other high-risk patients.
Comparison with existing treatments
Current options either remove tumours after they appear, or prevent them only partly, briefly or at a cost in side effects. None prevents both BCC and cSCC with a treatment patients can stay on.
Surgery (excision, Mohs surgery, curettage, cryotherapy). The standard of care. It treats each tumour after it appears and does nothing to prevent the next. People with Gorlin syndrome averaged about 28 surgeries a year before drug treatment, with cumulative scarring, often on the face. Market: US spending on skin cancer treatment averaged $8.1 billion a year in 2007-2011, of which $4.8 billion was for non-melanoma (keratinocyte) skin cancers.
Radiotherapy. Avoided in Gorlin syndrome because it induces new tumours, and limited in multiple BCC by overlapping treatment fields. Market: part of the procedure spending above; not reported separately.
Topical field treatments (5-fluorouracil, imiquimod, photodynamic therapy). A single course of 5-fluorouracil cream cut cSCCs needing surgery by 75% in the first year, but the effect was gone by the second, it did not significantly reduce BCC, and 21% of patients rated the side effects severe. Market: these products are sold mainly for actinic keratosis, a treatment market that commercial research firms put at about $7-9 billion a year worldwide in 2025 (unaudited estimates that vary between firms, and include procedures); topical drugs make up under half. Ameluz, a branded photodynamic therapy, had US sales of $42 million in 2025.
Nicotinamide (vitamin B3). Cheap and well tolerated. It reduced new keratinocyte cancers by 23% in people with previous skin cancers, but showed no benefit in transplant recipients. Market: sold as an inexpensive over-the-counter supplement costing a few pounds a month; there is no meaningful prescription market.
Acitretin (oral retinoid). Used to reduce cSCC in transplant recipients. The effect lasts only while it is taken, side effects are common and it is teratogenic. Market: a generic drug, prescribed mainly for psoriasis; sales for skin cancer prevention are not reported separately and are small.
Switching transplant immunosuppression to sirolimus. In kidney recipients with a previous cSCC, new cSCCs fell from 39% to 22% over two years, but serious side effects were more frequent and 23% stopped the drug. Market: a generic immunosuppressant; no separate skin cancer market.
Hedgehog inhibitors (vismodegib, sonidegib). Highly effective against BCC (new BCCs cut from 29 to 2 per patient per year in Gorlin syndrome), and vismodegib is funded by NHS England for Gorlin syndrome and six or more BCCs. Muscle cramps, taste loss and hair loss force intermittent dosing, they are teratogenic, and they have no effect on cSCC. Market: Roche reported Erivedge (vismodegib) sales of CHF 263 million in 2025 (CHF 260 million in 2024), mainly for advanced BCC. Sun Pharma does not report Odomzo (sonidegib) sales separately.
In development: patidegib. A topical hedgehog-inhibitor gel that has completed a phase 3 trial for preventing facial BCCs in Gorlin syndrome, with results expected in late November 2026. Like other hedgehog inhibitors, it targets BCC only. Market: Sol-Gel's published guidance is peak annual sales of more than $300 million in Gorlin syndrome (about $320 million in its 2024 investor presentation); more recent investor-call summaries cite up to $600 million.
Immunotherapy for advanced cSCC (cemiplimab). Treats cSCC once it has spread rather than preventing it, and carries a risk of organ rejection in transplant recipients. Market: Libtayo (cemiplimab) global net sales were $1.45 billion in 2025, across its approved indications in cSCC, BCC and lung cancer, showing what payers will spend on keratinocyte cancer once it is advanced.
Key caveats
Price is the largest variable. The base case of £25,000 a year is benchmarked on vismodegib, which payers fund for the highest-burden patients (Gorlin syndrome, or six or more BCCs). Payers may limit a preventive at this price to similar high-burden patients, and cheap off-label options (nicotinamide, acitretin, topical 5-fluorouracil) compete in lower-risk groups.
Patient numbers depend on how "multiple" is defined and on registry data that under-count keratinocyte cancers - most registries record only the first tumour per patient.
Prevention trials are long and event-driven. Peak sales assume successful development, approval and adoption; this is a long-horizon projection, not a near-term revenue forecast.
The rest of the world is excluded.
Sources
Evans DG et al. Birth incidence and prevalence of tumour-prone syndromes. Am J Med Genet A 2010 (Gorlin syndrome about 1 in 31,000).
US basal cell nevus syndrome patient registry: burden of illness (BCCs per year and per lifetime).
Rogers HW et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol 2015;151:1081-6.
Asgari MM et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol 2015;151:976-81.
Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013;68:957-66.
Kwiatkowska M et al. An updated report on the incidence and epidemiological trends of keratinocyte cancers in the UK 2013-2018. Skin Health Dis 2021.
Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer. Arch Dermatol 2000;136:1524-30.
Eggermont C et al. Cumulative incidence and timing of subsequent cutaneous squamous cell carcinomas stratified for patients' characteristics. J Am Acad Dermatol 2024.
Mayo Clinic Proceedings, Skin Cancer in Solid Organ Transplant Recipients (65-100x SCC risk).
OPTN/SRTR Annual Data Reports (US transplant recipients).
NICE TA489, vismodegib for treating basal cell carcinoma (list price).
NHS England. Clinical Commissioning Policy: Vismodegib for adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas (210504P, URN 1905), July 2021.
Tang JY et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8; and 2016 extension study.
Chen AC et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention (ONTRAC). N Engl J Med 2015;373:1618-26.
Allen NC et al. Nicotinamide for skin-cancer chemoprevention in transplant recipients (ONTRANS). N Engl J Med 2023;388:804-12.
Weinstock MA et al. Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream (VAKCC). JAMA Dermatol 2018;154:167-74.
Euvrard S et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation (TUMORAPA). N Engl J Med 2012;367:329-39.
Puza CJ, Cardones AR, Mosca PJ. Timing and number of cutaneous squamous cell carcinomas in transplant recipients. JAMA Dermatol 2018;154:727-8.
Harwood CA et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant 2013.
Bouwes Bavinck JN et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996;61:715-21.
Wisgerhof HC et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010.
Garrett GL et al. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol 2017;153:296-303.
Guy GP et al. Prevalence and costs of skin cancer treatment in the US, 2002-2006 and 2007-2011. Am J Prev Med 2015;48:183-7.